Melanoma and genetics

Clinics in Dermatology

Volumn 27, Issue 1, 2009, Pages 46-52

  Nelson, Andrew A ^a   Tsao, Hensin ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MELANOCORTIN 1 RECEPTOR; PROTEIN P107;

APOPTOSIS; ARTICLE; CANCER RISK; CARCINOGENESIS; CELL DIVISION; DNA DETERMINATION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE STRUCTURE; GENETIC PREDISPOSITION; GENETIC RISK; HEREDITY; HUMAN; MELANOMA; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TEST; TUMOR SUPPRESSOR GENE;

ALLELES; HUMANS; MELANOMA; RECEPTOR, MELANOCORTIN, TYPE 1; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS;

EID: 57449087434     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2008.09.005     Document Type: Article

References (27)

1. Watson J.D., and Crick F.H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171 (1953) 737-738
2. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
3. McCarroll S.A., and Altshuler D.M. Copy-number variation and association studies of human disease. Nat Genet 39 7 Suppl (2007) S37-S42
4. Clark Jr. W.H., Reimer R.R., Greene M., Ainsworth A.M., and Mastrangelo M.J. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome.'. Arch Dermatol 114 (1978) 732-738
5. Lynch H.T., Frichot B.C., and Lynch J.F. Familial atypical multiple mole-melanoma syndrome. J Med Genet 15 (1978) 352-356
6. Kamb A., Gruis N., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 (1994) 436
7. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., and Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753
8. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2a mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44 (2007) 99-106
9. Berwick M., Orlow I., Hummer A.J., et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 15 (2006) 1520-1525
10. Quelle D.E., Zindy F., Ashmun R.A., and Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83 (1995) 993-1000
11. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 (2001) 731-737
12. Lilischkis R., Sarcevic B., Kennedy C., Warlters A., and Sutherland R.L. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66 (1996) 249-254
13. Bothner B., Lewis W.S., DiGiammarino E.L., et al. Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 314 (2001) 263-277
14. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., and DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 (1996) 27-37
15. Chin L., Pomerantz J., Polsky D., et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11 (1997) 2822-2834
16. Sharpless E., and Chin L. The INK4a/ARF locus and melanoma. Oncogene 22 (2003) 3092-3098
17. Bishop D.T., Demenais F., Goldstein A.M., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94 (2002) 894-903
18. Begg C.B., Orlow I., Hummer A.J., et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 97 (2005) 1507-1515
19. Soufir N., Avril M.F., Chompret A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7 (1998) 209-216
20. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 (1996) 97-99
21. Chin L., Garraway L.E., and Fisher D. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20 (2006) 2149-2182
22. Rouzaud F., Kadekaro A.L., Abdel-Malek Z.A., and Hearing V.J. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 571 (2005) 133-152
23. Valverde P., Healy E., Jackson I., Rees J.L., and Thody A.J. Variants of the melanocytestimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11 (1995) 328-330
24. Raimondi S., Sera F., Gandini S., et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 122 (2008) 2753-2760
25. Box N.F., Duffy D.L., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
26. Kefford R., Bishop J.N., Tucker M., et al. Genetic testing for melanoma. Lancet Oncol 3 (2002) 653-654
27. Kefford R.F., Newton Bishop J.A., Bergman W., and Tucker M.A. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17 (1999) 3245-3251